BG Medicine Inc., a Waltham, Mass.-based developer of molecular diagnostics based on biomarkers, has set its IPO terms to six million shares being offered at between EUR 5.75 and EUR 7.25 per share. It plans to trade on Eurolist by Euronext Amsterdam under the symbol BGMDX, with Cowen International and Fortis serving as co-lead underwriters. BG Medicine has raised around $37 million in VC funding since 2000, from firms like Flagship Ventures (48.8% pre-IPO stake), Gilde Investment Management (14.6%) and Koniklijke Philips Electronics (6.5%).
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.